DJIA 17,001.22 -38.27 -0.22%
NASDAQ 4,538.55 6.45 0.14%
S&P 500 1,988.40 -3.97 -0.20%
market minute promo

United Therapeutics Corp (NASDAQ: UTHR)



company name or ticker
Company Photos
(Click to zoom)

United Therapeutics: 7 Different Insiders Have Sold Shares This Month

Today’s Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam

Insmed, Exelixis, United Therapeutics, and Alnylam could all make biotech headlines this morning. Here’s why.

Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive

Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook

SUPN: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook

United Therapeutics: A Profitable Biotech With A Potentially Undervalued Pipeline

Catalysts That Could Push Top Biotech Stocks Even Higher

InterMune Stuns Markets, but Is It Overvalued?

Trial results for Intermune's Esbriet launched shares higher this month; however, the opportunity may not justify shares heading much higher from here.

Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

United Therapeutics Slips on Q4 Earnings Report - Analyst Blog

First Week of April 19th Options Trading For United Therapeutics (UTHR)

See More Articles...